Reuters logo
BRIEF-Novo Nordisk receives FDA approval for Tresiba's use in children
December 19, 2016 / 7:18 PM / a year ago

BRIEF-Novo Nordisk receives FDA approval for Tresiba's use in children

Dec 19 (Reuters) - Novo Nordisk A/S

* Says received U.S. FDA approval of Tresiba (insulin degludec injection 100 u/ml, 200 u/ml) for use in children and adolescents with diabetes.

* Says Tresiba, first approved by the FDA in September 2015, is now indicated to improve glycaemic control in patients with type 1 and type 2 diabetes from the age of one through to adulthood.

* Source text for Eikon: Further company coverage: (Reporting by Jacob Gronholt-Pedersen; Editing by Greg Mahlich)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below